Next Article in Journal
Epigallocatechin-3-Gallate (EGCG), an Active Compound of Green Tea Attenuates Acute Lung Injury Regulating Macrophage Polarization and Krüpple-Like-Factor 4 (KLF4) Expression
Next Article in Special Issue
The Spectroscopic Similarity between Breast Cancer Tissues and Lymph Nodes Obtained from Patients with and without Recurrence: A Preliminary Study
Previous Article in Journal
Identification of Selected Antibiotic Resistance Genes in Two Different Wastewater Treatment Plant Systems in Poland: A Preliminary Study
Article

Assessment of Raman Spectroscopy for Reducing Unnecessary Biopsies for Melanoma Screening

1
Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA
2
Department of Medicine, The University of Texas at Austin, Austin, TX 78712, USA
3
Department of Integrative Biology, The University of Texas at Austin, Austin, TX 78712, USA
4
Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Derek J. McPhee
Molecules 2020, 25(12), 2852; https://doi.org/10.3390/molecules25122852
Received: 21 May 2020 / Revised: 12 June 2020 / Accepted: 18 June 2020 / Published: 20 June 2020
(This article belongs to the Special Issue A New Diagnosis Tool of Cancer by Spectroscopic Analysis)
A key challenge in melanoma diagnosis is the large number of unnecessary biopsies on benign nevi, which requires significant amounts of time and money. To reduce unnecessary biopsies while still accurately detecting melanoma lesions, we propose using Raman spectroscopy as a non-invasive, fast, and inexpensive method for generating a “second opinion” for lesions being considered for biopsy. We collected in vivo Raman spectral data in the clinical skin screening setting from 52 patients, including 53 pigmented lesions and 7 melanomas. All lesions underwent biopsies based on clinical evaluation. Principal component analysis and logistic regression models with leave one lesion out cross validation were applied to classify melanoma and pigmented lesions for biopsy recommendations. Our model achieved an area under the receiver operating characteristic (ROC) curve (AUROC) of 0.903 and a specificity of 58.5% at perfect sensitivity. The number needed to treat for melanoma could have been decreased from 8.6 (60/7) to 4.1 (29/7). This study in a clinical skin screening setting shows the potential of Raman spectroscopy for reducing unnecessary skin biopsies with in vivo Raman data and is a significant step toward the application of Raman spectroscopy for melanoma screening in the clinic. View Full-Text
Keywords: melanoma; skin screening; Raman spectroscopy; classification; specificity melanoma; skin screening; Raman spectroscopy; classification; specificity
Show Figures

Graphical abstract

MDPI and ACS Style

Zhang, Y.; Moy, A.J.; Feng, X.; Nguyen, H.T.M.; Sebastian, K.R.; Reichenberg, J.S.; Wilke, C.O.; Markey, M.K.; Tunnell, J.W. Assessment of Raman Spectroscopy for Reducing Unnecessary Biopsies for Melanoma Screening. Molecules 2020, 25, 2852. https://doi.org/10.3390/molecules25122852

AMA Style

Zhang Y, Moy AJ, Feng X, Nguyen HTM, Sebastian KR, Reichenberg JS, Wilke CO, Markey MK, Tunnell JW. Assessment of Raman Spectroscopy for Reducing Unnecessary Biopsies for Melanoma Screening. Molecules. 2020; 25(12):2852. https://doi.org/10.3390/molecules25122852

Chicago/Turabian Style

Zhang, Yao, Austin J. Moy, Xu Feng, Hieu T.M. Nguyen, Katherine R. Sebastian, Jason S. Reichenberg, Claus O. Wilke, Mia K. Markey, and James W. Tunnell 2020. "Assessment of Raman Spectroscopy for Reducing Unnecessary Biopsies for Melanoma Screening" Molecules 25, no. 12: 2852. https://doi.org/10.3390/molecules25122852

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop